#JS212
LightNews LightNews
newsen.bsky.social
BioDlink Celebrates Junshi Biosciences' IND Approval for JS212 Therapy#China#Suzhou#BioDlink#Junshi_Biosciences#JS212
BioDlink Celebrates Junshi Biosciences' IND Approval for JS212 Therapy
BioDlink proudly announces Junshi Biosciences' IND approval for JS212, a bispecific ADC aimed at treating various cancers. This milestone showcases advanced therapeutic advancements.
third-news.com
May 8, 2025 at 12:57 PM
canadareport.org
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH P...

Canada’s fastest news scan: 25+ headlines, no clutter, updated all day: CanadaReport.org

#cdnpoli #Canada #News #Business #Economy
Read Original Article 🔗
April 20, 2026 at 10:31 PM
l2plabs.bsky.social
BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate
BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212, the company's first bispecific ADC. JS212 combines dual-targeting antibody technology with a cytotoxic payload, representing a next-generation therapeutic. BioDlink provided end-to-end...
dlvr.it
May 8, 2025 at 12:33 PM
marketwire.bsky.social
📰 #Finance

"SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced…"
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
financialpost.com
April 20, 2026 at 10:30 PM